Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38554946)

  • 1. Molecular and functional insight into anti-EGFR nanobody: Theranostic implications for malignancies.
    Tripathy RK; Pande AH
    Life Sci; 2024 May; 345():122593. PubMed ID: 38554946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
    Roovers RC; Vosjan MJ; Laeremans T; el Khoulati R; de Bruin RC; Ferguson KM; Verkleij AJ; van Dongen GA; van Bergen en Henegouwen PM
    Int J Cancer; 2011 Oct; 129(8):2013-24. PubMed ID: 21520037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation and characterization of humanized nanobodies targeting the dimer interface of epidermal growth factor receptor (EGFR).
    Zhu H; Zhao L; Li Z; Wen B; Qiu C; Liu M; Xu Z; Hu S; Li H
    Protein Expr Purif; 2019 May; 157():57-62. PubMed ID: 30735705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paper Title "Hu7CG2: A Novel Humanized Anti-Epidermal Growth Factor Receptor (EGFR) Biparatopic Nanobody".
    Sharifi J; Khirehgesh MR; Akbari B; Soleymani B; Mansouri K
    Mol Biotechnol; 2021 Jun; 63(6):525-533. PubMed ID: 33772436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR targeted nanobody-photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer.
    van Driel PBAA; Boonstra MC; Slooter MD; Heukers R; Stammes MA; Snoeks TJA; de Bruijn HS; van Diest PJ; Vahrmeijer AL; van Bergen En Henegouwen PMP; van de Velde CJH; Löwik CWGM; Robinson DJ; Oliveira S
    J Control Release; 2016 May; 229():93-105. PubMed ID: 26988602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformational nanobodies reveal tethered epidermal growth factor receptor involved in EGFR/ErbB2 predimers.
    Nevoltris D; Lombard B; Dupuis E; Mathis G; Chames P; Baty D
    ACS Nano; 2015 Feb; 9(2):1388-99. PubMed ID: 25603171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects.
    van de Water JA; Bagci-Onder T; Agarwal AS; Wakimoto H; Roovers RC; Zhu Y; Kasmieh R; Bhere D; Van Bergen en Henegouwen PM; Shah K
    Proc Natl Acad Sci U S A; 2012 Oct; 109(41):16642-7. PubMed ID: 23012408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study and evaluation of anti-EGFR nanobodies expressed in Pichia pastoris and Escherichia coli as antitumor moieties.
    Xi X; Sun W; Li H; Fan Q; Zhang X; Sun F
    Protein Expr Purif; 2021 Aug; 184():105888. PubMed ID: 33857600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies.
    Roovers RC; Laeremans T; Huang L; De Taeye S; Verkleij AJ; Revets H; de Haard HJ; van Bergen en Henegouwen PM
    Cancer Immunol Immunother; 2007 Mar; 56(3):303-317. PubMed ID: 16738850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient growth inhibition of EGFR over-expressing tumor cells by an anti-EGFR nanobody.
    Omidfar K; Amjad Zanjani FS; Hagh AG; Azizi MD; Rasouli SJ; Kashanian S
    Mol Biol Rep; 2013 Dec; 40(12):6737-45. PubMed ID: 24052234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-EGFR Binding Nanobody Delivery System to Improve the Diagnosis and Treatment of Solid Tumours.
    Wang L; Zhang G; Qin L; Ye H; Wang Y; Long B; Jiao Z
    Recent Pat Anticancer Drug Discov; 2020; 15(3):200-211. PubMed ID: 32885759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-penetrable nanobodies (transbodies) that inhibit the tyrosine kinase activity of EGFR leading to the impediment of human lung adenocarcinoma cell motility and survival.
    Tabtimmai L; Suphakun P; Srisook P; Kiriwan D; Phanthong S; Kiatwuthinon P; Chaicumpa W; Choowongkomon K
    J Cell Biochem; 2019 Oct; 120(10):18077-18087. PubMed ID: 31172597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a novel anti-EGFR nanobody by phage display and its distinct paratope and epitope via homology modeling and molecular docking.
    Xi X; Sun W; Su H; Zhang X; Sun F
    Mol Immunol; 2020 Dec; 128():165-174. PubMed ID: 33130376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A camelid nanobody against EGFR was easily obtained through refolding of inclusion body expressed in Escherichia coli.
    Xu L; Song X; Jia L
    Biotechnol Appl Biochem; 2017 Nov; 64(6):895-901. PubMed ID: 28853185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production of a mono-biotinylated EGFR nanobody in the E. coli periplasm using the pET22b vector.
    Noor A; Walser G; Wesseling M; Giron P; Laffra AM; Haddouchi F; De Grève J; Kronenberger P
    BMC Res Notes; 2018 Oct; 11(1):751. PubMed ID: 30348204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR and anti-EGFR nanobodies: review and update.
    Sharifi J; Khirehgesh MR; Safari F; Akbari B
    J Drug Target; 2021 Apr; 29(4):387-402. PubMed ID: 33210573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice.
    Xenaki KT; Dorrestijn B; Muns JA; Adamzek K; Doulkeridou S; Houthoff H; Oliveira S; van Bergen En Henegouwen PM
    Theranostics; 2021; 11(11):5525-5538. PubMed ID: 33859761
    [No Abstract]   [Full Text] [Related]  

  • 18. Structural insights into the non-inhibitory mechanism of the anti-EGFR EgB4 nanobody.
    Zeronian MR; Doulkeridou S; van Bergen En Henegouwen PMP; Janssen BJC
    BMC Mol Cell Biol; 2022 Mar; 23(1):12. PubMed ID: 35232398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multivalent biparatopic EGFR-targeting nanobody drug conjugate displays potent anticancer activity in solid tumor models.
    Fan J; Zhuang X; Yang X; Xu Y; Zhou Z; Pan L; Chen S
    Signal Transduct Target Ther; 2021 Sep; 6(1):320. PubMed ID: 34475375
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.